MAPKAPK2 and neoplasm: MK2 inhibitors have recently been shown to inhibit tumor proliferation and metastasis and increase the efficacy of other agents,[21, 60, 63] and an oral MK2 inhibitor, ATI‐450, which prevents MK2 activation by inhibiting the p38‐MAPK‒MK2 interaction,[64] is currently being evaluated in a phase 1/2 clinical trial for individuals with metastatic breast cancer (NCT06374459).